Neurocritical Care

, Volume 13, Issue 2, pp 263–277

Treatment of Subarachnoid Hemorrhage with Human Albumin: ALISAH Study. Rationale and Design

Taking A Closer Look At Trials

Abstract

The primary objective of this prospective dose-finding pilot study is to demonstrate the tolerability and safety of four dosages of 25% human albumin in patients with subarachnoid hemorrhage (SAH). For each dosage group, the study will enroll 20 patients who meet the eligibility criteria. The enrolled patients will undergo follow-up for 90 days post-treatment. The primary tolerability hypothesis is that intravenous 25% human albumin can be given without precipitating treatment related serious adverse events beyond expectations. The study will determine the maximum tolerated dosage of 25% human albumin therapy based on the rate of treatment related serious adverse events during treatment: severe or life-threatening heart failure. The secondary objectives are to obtain preliminary estimates of the albumin treatment effect using the incidence of neurological deterioration within 15 days after symptom onset. In addition, the incidence of rebleeding, hydrocephalus, seizures, delayed cerebral ischemia and the incidence of vasospasm (both symptomatic and by transcranial Doppler ultrasound criteria) within 15 days after symptom onset will be evaluated. Furthermore, the serum osmolality and serum albumin concentrations, serum magnesium concentration, blood pressure and heart rate within 15 days of symptom onset will also be observed. The Glasgow Outcome Scale, Barthel Index, modified Rankin Scale, NIH Stroke Scale, and Stroke Impact Scale will be performed 3 months after the onset of symptoms to assess residual neurological deficits.

Keywords

Subarachnoid hemorrhage Clinical trial Albumin Intracranial aneurysm Drug therapy 

References

  1. 1.
    Sudlow CLM, Warlow CP. Comparable studies of the incidence of stroke and its pathological types. Results from an international collaboration. Stroke. 1997;28:491–9.PubMedGoogle Scholar
  2. 2.
    Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1994;25:2315–28.PubMedGoogle Scholar
  3. 3.
    van Gijn J, Rinkel JE. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001;124:249–78.CrossRefPubMedGoogle Scholar
  4. 4.
    Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke. 1997;28:660–4.PubMedGoogle Scholar
  5. 5.
    Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998;50:1413–8.PubMedGoogle Scholar
  6. 6.
    Roos YBWEM, Dijkgraaf MGW, Albrecht KW, et al. Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis. Stroke. 2002;33:1595–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Haley EC, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1993;78:537–47.CrossRefPubMedGoogle Scholar
  8. 8.
    Haley EC, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. J Neurosurg. 1993;78:548–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Hijdra A, van Gijn J, Nagelkerke NJD, Vermeulen M, van Crevel H. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19:1250–6.PubMedGoogle Scholar
  10. 10.
    Hijdra A, Vermeulen M, van Gijn J, van Crevel H. Rerupture of intracranial aneurysms: a clinicoanatomic study. J Neurosurg. 1987;67:29–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Kassell NF, Torner JC, Haley EC, et al. The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg. 1990;73:18–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Kassell NF, Torner JC, Jane JA, Haley EC, Adams HP. The international cooperative study on the timing of aneurysm surgery. Part 2; surgical results. J Neurosurg. 1990;73:37–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Solenski N, Haley EC, Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Crit Care Med. 1995;23:1007–17.CrossRefPubMedGoogle Scholar
  14. 14.
    van Gijn J, Bromberg JEC, Lindsay KW, Hasan D, Vermeulen M. Definition of initial grading, specific events, and overall outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 1994;25:1623–7.PubMedGoogle Scholar
  15. 15.
    Hijdra A, van Gijn J, Stefanko S, van Dongen KJ, Vermeulen M, van Crevel H. Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: clinicoanatomic correlations. Neurology. 1986;36:329–33.PubMedGoogle Scholar
  16. 16.
    Dietrich HH, Dacey RG. Molecular keys to the problems of cerebral vasospasm. Neurosurgery. 2000;46:517–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Macdonald RL. Pathophysiology and molecular genetics of vasospasm. Acta Neurochir. 2001;S77:7–11.Google Scholar
  18. 18.
    Bulter WE, Peterson JW, Zervas NT, Morgan KG. Intracellular calcium, myosin light chain phosphorylation, and contractile force in experimental cerebral vasospasm. Neurosurgery. 1996;38:781–8.PubMedGoogle Scholar
  19. 19.
    Koide M, Nishizawa S, Ohta S, Yokoyama T, Namba H. Chronological changes of the contractile mechanism in prolonged vasospasm after subarachnoid hemorrhage: from protein kinase C to protein tyrosine kinase. Neurosurgery. 2002;51:1468–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Laher I, Zhang JH. Protein kinase C and cerebral vasospasm. J Cereb Blood Flow. 2001;2:887–906.CrossRefGoogle Scholar
  21. 21.
    Clatterbuck RE, Oshiro EM, Hoffman PA, Dietsch GN, Pardoli DM, Tamargo RJ. Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. J Neurosurg. 2002;97:676–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Mocco J, Mack WJ, Kim GH, et al. Rise in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;97:537–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol. 2002;88:227–49.CrossRefPubMedGoogle Scholar
  24. 24.
    Thai Q-A, Oshiro EM, Tamargo RJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke. 1999;30:140–7.PubMedGoogle Scholar
  25. 25.
    Borel CO, McKee A, Parra A, et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke. 2003;34:427–33.CrossRefPubMedGoogle Scholar
  26. 26.
    McGirt MJ, Lynch JR, Blessing R, et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular-endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;51:1128–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Ono S, Komuro T, Macdonald LR. Heme oxygenase-1 gene therapy for prevention of vasospasm in rats. J Neurosurg. 2002;96:1094–102.CrossRefPubMedGoogle Scholar
  28. 28.
    Auer LM. Acute operation and preventive nimodipine improve outcome in patients with ruptured cerebral aneurysms. Neurosurgery. 1984;15:57–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Flamm ES, Adams HP, Beck DW, et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1988;68:393–400.CrossRefPubMedGoogle Scholar
  30. 30.
    Gilsbach JM, Reulen HJ, Ljunggren B, et al. Early aneurysm surgery and preventive therapy with intravenously administered nimodipine: a multicenter, double-blind, dose-comparison study. Neurosurgery. 1990;26:458–64.CrossRefPubMedGoogle Scholar
  31. 31.
    Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. J Neurosurg. 1988;68:505–17.CrossRefPubMedGoogle Scholar
  32. 32.
    Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Rinkel GJ, Feigin VL, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst Rev. 2000;4:CD000277.Google Scholar
  34. 34.
    Alderson P, Schierhout G, Roberts I, Bunn F. Colloid versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2000;2:CD000567.PubMedGoogle Scholar
  35. 35.
    The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.CrossRefGoogle Scholar
  36. 36.
    Wilkes MM, Navickis RJ. Patient survival after human albumin administration. Ann Intern Med. 2001;135:149–64.PubMedGoogle Scholar
  37. 37.
    Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg. 1997;87:595–601.CrossRefPubMedGoogle Scholar
  38. 38.
    Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32:553–60.PubMedGoogle Scholar
  39. 39.
    Belayev L, Pinard E, Nallet H, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 2002;33:1077–84.CrossRefPubMedGoogle Scholar
  40. 40.
    Belayev L, Saul I, Huh PW, et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res. 1999;845:107–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Cole DJ, Drummond JC, Osborne TN, Matsumura J. Hypertension and hemodilution during cerebral ischemia reduce brain injury and edema. Am J Physiol. 1990;259:H211–7.PubMedGoogle Scholar
  42. 42.
    Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res. 1998;804:105–13.CrossRefPubMedGoogle Scholar
  43. 43.
    Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol. 2001;428:193–201.CrossRefPubMedGoogle Scholar
  44. 44.
    Matsui T, Sinyama H, Asano T. Beneficial effect of prolonged administration of albumin on ischemic cerebral edema and infarction after occlusion of middle cerebral artery in rats. Neurosurgery. 1993;33:293–300.CrossRefPubMedGoogle Scholar
  45. 45.
    Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma. 1999;16:445–53.CrossRefPubMedGoogle Scholar
  46. 46.
    Matsui T, Asano T. The hemodynamic effects of prolonged albumin administration in beagle dogs exposed to experimental subarachnoid hemorrhage. Neurosurgery. 1993;32:79–83.CrossRefPubMedGoogle Scholar
  47. 47.
    Belayev L, Zhao W, Pattany PM, et al. Diffusion-weighted resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29:2587–99.PubMedGoogle Scholar
  48. 48.
    Asplund K. Hemodilution for acute ischemic stroke. Cochrane Database Syst Rev. 2002;4:CD000103.PubMedGoogle Scholar
  49. 49.
    Tomita H, Ito U, Tone O, Masaoka H, Tominaga B. High colloid oncotic therapy for contusional brain edema. Acta Neurochir Suppl (Wien). 1994;60:547–9.Google Scholar
  50. 50.
    Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigten T, Romner B. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49:593–606.CrossRefPubMedGoogle Scholar
  51. 51.
    Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–91.PubMedGoogle Scholar
  52. 52.
    Mayer SA, Solomon RA, Fink ME, et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery. 1998;42:759–68.CrossRefPubMedGoogle Scholar
  53. 53.
    Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS Pilto Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke—I: physiological responses and safety results. Stroke. 2006;37:2100–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke. 2006;37:2107–14.CrossRefPubMedGoogle Scholar
  55. 55.
    Suarez JI, Shannon L, Zaidat OO, et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with SAH. J Neurosurg. 2004;100:585–90.CrossRefPubMedGoogle Scholar
  56. 56.
    Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28:14–20.CrossRefPubMedGoogle Scholar
  57. 57.
    Lindsay KW, Teasdale G, Knill-Jones RP, Murray L. Observer variability in grading patients with subarachnoid hemorrhage. J Neurosurg. 1982;56:628–33.CrossRefPubMedGoogle Scholar
  58. 58.
    Lindsay KW, Teasdale GM, Knill-Jones RP. Observer variability in assessing the clinical features of subarachnoid hemorrhage. J Neurosurg. 1983;58:57–62.CrossRefPubMedGoogle Scholar
  59. 59.
    Drake CG, Hunt WE, Sano K, et al. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg. 1988;68:985–6.Google Scholar
  60. 60.
    Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1977;2:81–4.Google Scholar
  61. 61.
    Teasdale G, Knill-Jones R, van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry. 1978;41:603–10.CrossRefPubMedGoogle Scholar
  62. 62.
    Adams HP, Kassell NF, Torner JC, Haley EC. Predicting cerebral ischemia after aneurismal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology. 1987;37:1586–91.PubMedGoogle Scholar
  63. 63.
    Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk pf delayed cerebral ischemia after subarachnoid hemorrhage. The Fisher Scale revisited. Stroke. 2001;32:2012–20.CrossRefPubMedGoogle Scholar
  64. 64.
    Suarez JI, Qureshi AI, Yahia AB, et al. Symptomatic vasospasm diagnosis after subarachnoid hemorrhage: evaluation of transcranial Doppler ultrasound and cerebral angiography as related to the compromised vascular distribution. Crit Care Med. 2002;30:1348–55.CrossRefPubMedGoogle Scholar
  65. 65.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996–3007.CrossRefPubMedGoogle Scholar
  66. 66.
    Peters T. The albumin molecule: its structure and chemical properties. In: Peters T, editor. All about albumin: biochemistry, genetics, and clinical applications. San Diego: Academic Press; 1996. p. 9–75.Google Scholar
  67. 67.
    Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Torner JC, Nibbelink DW, Burmeister LF. Statistical comparisons of end results of a randomized treatment study. In: Sahs AL, Nibbelink DW, Torner JC, editors. Aneurysmal subarachnoid hemorrhage-report of the Cooperative Study. Baltimore: Urban & Schwrtzenberg; 1981. p. 249–75.Google Scholar
  69. 69.
    Suarez JI, Tarr R, Selman WR. Subarachnoid hemorrhage. Current concepts. N Engl J Med. 2006;354:387–96.CrossRefPubMedGoogle Scholar
  70. 70.
    Muizelaar JP, Zwienenberg M, Rudisill NA, Hecht ST. The prophylactic use of transluminal balloon angioplasty in patients with Fischer grade 3 subarachnoid hemorrhage: a pilot. J Neurosurg. 1999;91:51–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Hasan D, Wijdicks EFM, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol. 1990;27:106–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Wijdicks EF, Vermeulen M, ten Haaf JA, Hijdra A, Bakker WH, van Gijn J. Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm. Ann Neurol. 1985;18:211–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72.CrossRefPubMedGoogle Scholar
  74. 74.
    Bellone A, Monari A, Cortellano F, Vettorello M, Arlati S, Coen D. Myocardial infarction rate in acute pulmonary edema: noninvasive pressure support ventilation versus continuous positive airway pressure. Crit Care Med. 2004;32:1860–5.CrossRefPubMedGoogle Scholar
  75. 75.
    Mehta S, Jay G, Woolard R, Hipona R, Connolly E, Cimini D, Drinkwine J, Hill N. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med. 1997;25:620–8.CrossRefPubMedGoogle Scholar
  76. 76.
    van Gijn J, Hijdra A, Widjicks EFM, Vermeulen M, van Crevel H. Acute hydrocephalus after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1985;63:355–62.CrossRefPubMedGoogle Scholar
  77. 77.
    Meese W, Kluge W, Grumme T, Hopfenmuller W. CT evaluation of the CSF spaces of healthy persons. Neuroradiology. 1980;19:131–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Neurology, Divisions Vascular Neurology and Neurocritical CareBaylor College of MedicineHoustonUSA
  2. 2.Department of Medicine, Division of Biostatistics, Bioinformatics and EpidemiologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations